Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1743351 10.3389/fphar.2025.1743351 Correction Correction: Methodological study protocol for the European Atlas of clinical trials in cancer and haematology Cases et al. 10.3389/fphar.2025.1743351 Cases Mercè 1 * Writing - original draft Writing - review and editing Giles Rachel 2 * Writing - original draft Writing - review and editing Ágh Tamás 3 Writing - original draft Writing - review and editing Piggin Maria 4 Writing - original draft Writing - review and editing Geissler Jan 1 5 Writing - original draft Writing - review and editing Racovita Monica 6 Writing - original draft Writing - review and editing Hagymásy Judit 3 Writing - original draft Writing - review and editing Ruth Wogu Lora 7 Writing - original draft Writing - review and editing Józwiak Ákos 3 Writing - original draft Writing - review and editing Hyseni-Bocolli Albina 8 Writing - original draft Writing - review and editing Hosszú Dalma 3 9 † Writing - original draft Writing - review and editing Plate Ananda 1 2 † Writing - original draft Writing - review and editing EuroACT Working Group European Patient Advocacy Institute, Riemerling, Germany VHL Europa, Vlaardingen, Netherlands Syreon Research Institute, Budapest, Hungary PNH Global Alliance, Tiel, Netherlands Workgroup of European Cancer Patient Advocacy Networks, Barcelona, Spain Myeloma Patients Europe, Brussels, Belgium European Sickle Cell Federation-ESCF, Dublin, Ireland Childhood Cancer International – Europe, Vienna, Austria University of Pécs Institute of Psychology, Pécs, Hungary Correspondence: Mercè Cases, merce.cases@patientadvocacy.eu; Rachel Giles, rachelhelengiles@gmail.com

These authors have contributed equally to this work and share last authorship

 21 11 2025 2025 16 1743351 10 11 2025 11 11 2025 Copyright © 2025 Cases, Giles, Ágh, Piggin, Geissler, Racovita, Hagymásy, Ruth Wogu, Józwiak, Hyseni-Bocolli, Hosszú, Plate and EuroACT Working Group. 2025 Cases, Giles, Ágh, Piggin, Geissler, Racovita, Hagymásy, Ruth Wogu, Józwiak, Hyseni-Bocolli, Hosszú, Plate and EuroACT Working Group https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Methodological study protocol for the European Atlas of clinical trials in cancer and haematology by Cases M, Giles R, Ágh T, Piggin M, Geissler J, Racovita M, Hagymásy J, Ruth Wogu L, Józwiak Á, Hyseni-Bocolli A, Hosszú D, Plate A and EuroACT Working Group (2025). Front. Pharmacol. 16:1558556. doi: 10.3389/fphar.2025.1558556 cancer haematology rare disease patient patient reported outcome clinical trials section-in-acceptance Drugs Outcomes Research and Policies

Authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú were erroneously assigned to affiliation 4 PNH Global Alliance, Tiel, Netherlands. This affiliation has now been removed for author Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.

Affiliation 3 Syreon Research Institute, Budapest, Hungary was omitted for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú. This affiliation has now been added for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.

The collaborative group EuroACT Working Group was erroneously not credited with authorship in the published article. The consortium should be credited with authorship.

The list of members of the EuroACT Working Group was omitted from the published article. The section Group Members of the EuroACT Working Group has been added to the article as follows: Attila Imre, Anna Bögös, Natacha Bolaños, Susanna Leto di Priolo, Kate Morgan.

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland